Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Lurtotecan in Metastatic or Recurrent Head and Neck Cancer
NCT00022594Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2001
- Primary completion
- Aug 2002
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of lurtotecan liposome in squamous cell carcinoma of the head and neck (HNSCC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective Response. Started May 2001; status: completed.
02
Drugs
lurtotecan liposome
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00022594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022594.